½ÃÀ庸°í¼­
»óǰÄÚµå
1321420

µ¿¹°¿ë Á¤¸ÆÁÖ»ç¾× ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Á¦Ç°º°, µ¿¹° À¯Çüº°, ÀûÀÀÁõº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2023-2030³â)

Veterinary Intravenous (IV) Solutions Market Size, Share & Trends Analysis Report By Product, By Animal Type (Companion Animals, Production Animals), By Indication, By End-use, By Region, And Segment Forecasts, 2023 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 150 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

µ¿¹°¿ë Á¤¸ÆÁÖ»ç¾× ½ÃÀå ¼ºÀå ¹× µ¿Çâ

Grand View Research, IncÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°è µ¿¹° Á¤¸Æ ÁÖ»ç ½ÃÀå ±Ô¸ð´Â 2023³âºÎÅÍ 2030³â±îÁö 8.37%ÀÇ CAGR·Î È®´ëµÇ¾î 2030³â¿¡´Â 26¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ·¯ÇÑ ¼ºÀåÀÇ ¿øµ¿·ÂÀº µ¿¹°º¹Áö¿¡ ´ëÇÑ ÀνÄÀÇ Áõ°¡, µ¿¹°ÀÇ·áÀÇ ¹ßÀü, ¹Ý·Áµ¿¹° »çÀ°ÀÇ Áõ°¡, źÀúº´, ÃéÀå¿°, ±¸³»¿°°ú °°Àº Áúº´ÀÇ À¯Çà Áõ°¡ µîÀÔ´Ï´Ù. µ¿¹° ÀÇÇÐÀÇ ¹ßÀüÀ¸·Î µ¿¹°ÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â Ä¡·á ¿É¼ÇÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. µ¿¹°º´¿ø°ú Áø·á¼Ò¿¡´Â Á¤¸ÆÁÖ»ç ½Ã½ºÅÛ°ú °°Àº ÷´Ü Áø´Ü ¹× Ä¡·á Àåºñ°¡ °®Ãß¾îÁ® ÀÖ¾î ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

µ¿¹°À» À§ÇØ Æ¯º°È÷ °í¾ÈµÈ ÷´Ü ¼ö¾× ½Ã½ºÅÛÀÇ °³¹ß·Î ÀÎÇØ Åõ¾à °úÁ¤ÀÌ ´õ¿í È¿À²ÀûÀ̰í Á¤È®ÇÏ¸ç ¾ÈÀüÇØÁ³½À´Ï´Ù. Ư¼ö ¼ö¾× ÆßÇÁ ¹× ¼ö¾× ¸ð´ÏÅ͸µ ½Ã½ºÅÛ°ú °°Àº ÀÌ·¯ÇÑ ±â¼ú ¹ßÀüÀº ȯÀÚ Ä¡·á¸¦ °­È­Çϰí ÇÕº´Áõ À§ÇèÀ» ÁÙÀÓÀ¸·Î½á µ¿¹°¿ë Á¤¸ÆÁÖ»ç »ê¾÷¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¸¹Àº Áö¿ª¿¡¼­ °¡Ã³ºÐ ¼Òµæ ¼öÁØÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¹Ý·Áµ¿¹° ÀÇ·áºñ ÁöÃâÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¹Ý·Áµ¿¹° º¸È£ÀÚµéÀº ¼ö¾× ¿ä¹ýÀ» Æ÷ÇÔÇÑ ¾çÁúÀÇ ¼öÀÇÇп¡ ´õ ±â²¨ÀÌ ÅõÀÚÇÒ ÀÇÇâÀÌ ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

COVID-19 ÀÌÈÄ µ¿¹°¿ë Á¤¸ÆÁÖ»ç¾× »ê¾÷¿¡ ¹ÌÄ¡´Â ¿µÇâÀº ¼¼°è »óȲÀÌ °è¼Ó ÁøÈ­ÇÔ¿¡ µû¶ó ¾ÆÁ÷ ¹àÇôÁöÁö ¾Ê¾ÒÀ¸¸ç, COVID-19 ÆÒµ¥¹ÍÀÇ È¸º¹À¸·Î ¼ö¼ú, Ä¡·á ¹× ½É°¢ÇÑ »óȲ¿¡¼­ µ¿¹°¿¡°Ô Á¦°øµÇ´Â Ç¥ÁØ Ä¡·áÀÇ ÀϺηΠµ¿¹°¿ë Á¤¸ÆÁÖ»ç¾×¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÆÒµ¥¹ÍÀÇ °æÁ¦Àû ¿µÇâÀº ¹Ý·Áµ¿¹° º¸È£ÀÚ¿Í µ¿¹°º´¿øÀ» Æ÷ÇÔÇÑ ¸¹Àº °³Àΰú ±â¾÷¿¡ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. °æÁ¦Àû Á¦¾àÀÌ ¹Ý·Áµ¿¹° º¸È£ÀÚÀÇ ÀÇ»ç°áÁ¤ °úÁ¤¿¡ ¿µÇâÀ» ¹ÌÃÆÀ» ¼ö ÀÖÀ¸¸ç, ¼ö¾× »ç¿ëÀ» Æ÷ÇÔÇÑ ºñÇʼöÀûÀÎ ¼öÀÇÇÐÀû ½Ã¼ú ¹× Ä¡·á°¡ °¨¼ÒÇßÀ» ¼ö ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ¼öÀÇÇÐ ±³À° ÇÁ·Î±×·¥¿¡¼­ ¼ö¾× ¿ä¹ýÀÇ Á߿伺°ú ´Ù¾çÇÑ ÀÓ»ó »óȲ¿¡¼­ÀÇ ÀûÀýÇÑ »ç¿ëÀ» °­Á¶ÇÏ´Â µî ¿©·¯ °¡Áö ¿äÀÎÀ¸·Î ÀÎÇØ ºÏ¹Ì¿¡¼­ µ¿¹°¿ë Á¤¸ÆÁÖ»ç¾× »ç¿ë·üÀÌ »ó´ëÀûÀ¸·Î ³ôÀº ÆíÀÔ´Ï´Ù. ¼öÀÇ»ç ¹× ¼öÀÇ»çµéÀº ¼ö¾× Åõ¿©, ¸ð´ÏÅ͸µ ¹× °ü¸®¿¡ ´ëÇÑ ±¤¹üÀ§ÇÑ ±³À°À» ¹Þ¾ÒÀ¸¸ç, ¼ö¾×ÀÇ ÀûÀýÇÑ »ç¿ëÀ» ½ÇõÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ºÏ¹ÌÀÇ ¼öÀÇÇÐ Àü¹®°¡µéÀº µ¿¹°¿¡°Ô ¾çÁúÀÇ Ä¡·á¸¦ Á¦°øÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ¼ö¾× ¿ä¹ýÀº Á¾ÇÕÀûÀÎ ¼öÀÇÇÐ Ä¡·áÀÇ Áß¿äÇÑ ¿ä¼ÒÀ̸ç, ȯÀÚ Ä¡·á¸¦ ÃÖÀûÈ­ÇÏ°í µ¿¹°ÀÇ È¸º¹°ú °Ç°­À» Áö¿øÇϱâ À§ÇÑ ³ë·ÂÀÇ ÀÏȯÀ¸·Î ¼ö¾× ¿ä¹ýÀÇ Ã¤ÅÃÀÌ ÃßÁøµÇ°í ÀÖ½À´Ï´Ù.

µ¿¹°¿ë Á¤¸ÆÁÖ»ç¾× ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • Á¦Ç°º°·Î´Â µîÀå¾× ºÎ¹®ÀÌ 2022³â 42% ÀÌ»óÀÇ Á¡À¯À²À» Â÷ÁöÇÏ¸ç ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù. µ¿¹°ÀÇ ¼öºÐ °ø±Þ°ú ÀüÇØÁú ±ÕÇüÀ» ȸº¹Çϰí À¯ÁöÇϱâ À§ÇØ µ¿¹° ÀÇ·áÀÇ ¼ö¾× ¿ä¹ý¿¡¼­ µî¹æ¼º °áÁ¤¾×Àº ÀÚÁÖ »ç¿ëµË´Ï´Ù.
  • µ¿¹° À¯Çüº°·Î´Â ¹Ý·Áµ¿¹° ¼¼ºÐÈ­°¡ 2022³â ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù. ¸¹Àº °¡Á¤¿¡¼­ ¹Ý·Áµ¿¹°, ƯÈ÷ °³¿Í °í¾çÀ̸¦ Á¤±âÀûÀ¸·Î ¹Ý·Áµ¿¹°·Î Ű¿ì°í ÀÖ½À´Ï´Ù. ¹Ý·Áµ¿¹° »çÀ°Àº µ¿¹°¿ë Á¤¸ÆÁÖ»ç¾×¿¡ ´ëÇÑ Å« ¼ö¿ä·Î À̾îÁý´Ï´Ù. ÀÌ µ¿¹°µéÀº ´Ù¾çÇÑ °Ç°­ ¹®Á¦, ¼ö¼ú ¶Ç´Â ½É°¢ÇÑ Ä¡·á »óȲÀ¸·Î ÀÎÇØ Á¤¸Æ Áֻ簡 ÀÚÁÖ ÇÊ¿äÇϱ⠶§¹®ÀÔ´Ï´Ù.
  • ÀûÀÀÁõº°·Î´Â ´ç´¢º´¼º ÄÉÅæ»êÁõ(DKA) ºÎ¹®ÀÌ 2022³â ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù.
  • ÃÖÁ¾ ¿ëµµº°·Î´Â ¹Ý·Áµ¿¹°À» µ¿¹°º´¿ø¿¡ µ¥·Á°¡´Â »ç¶÷µéÀÌ Áõ°¡ÇÔ¿¡ µû¶ó µ¿¹°º´¿ø ºÎ¹®ÀÌ 2022³â 55% ÀÌ»óÀÇ ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù. Á¤¸Æ ¼ö¾× ¿ä¹ýÀº ȯÀÚ Ä¡·áÀÇ Áß¿äÇÑ ºÎºÐÀ¸·Î µ¿¹° º´¿ø¿¡¼­ ÀÚÁÖ »ç¿ëµË´Ï´Ù.
  • ºÏ¹Ì Áö¿ªÀº 2022³â ½ÃÀå Á¡À¯À²ÀÌ 38.0%¸¦ ³Ñ¾î °¡Àå ³ôÀº ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ºÏ¹Ì´Â ¹Ý·Áµ¿¹° º¸À¯À²ÀÌ ³ô¾Æ ¸¹Àº °¡Á¤¿¡¼­ °³, °í¾çÀÌ, ¼ÒÇü Æ÷À¯·ù¿Í °°Àº ¹Ý·Áµ¿¹°À» Ű¿ì°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

  • ½ÃÀå ¼¼ºÐÈ­¿Í ¹üÀ§
  • Á¶»ç ¹æ¹ý
  • Á¤º¸ Á¶´Þ
  • Á¤º¸ ¶Ç´Â µ¥ÀÌÅÍ ºÐ¼®
  • ½ÃÀå Çü¼º°ú °ËÁõ
  • ¸ðµ¨ »ó¼¼
  • µ¥ÀÌÅÍ ¼Ò½º ¸®½ºÆ®

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå µ¿¹°¿ë Á¤¸ÆÁÖ»ç¾× ½ÃÀå º¯¼ö, µ¿Çâ ¹× ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • »óºÎ ½ÃÀå Àü¸Á
    • ºÎ¼ö ½ÃÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
    • ½ÃÀå ±âȸ ºÐ¼®
    • ½ÃÀå °úÁ¦ ºÐ¼®
  • µ¿¹°¿ë Á¤¸ÆÁÖ»ç¾× ½ÃÀå ºÐ¼® Åø
    • ¾÷°è ºÐ¼® - Porter's
    • PESTEL ºÐ¼®
    • °¡°Ý ºÐ¼®
    • ÁÖ¿ä ±¹°¡º° ÃßÁ¤ µ¿¹° °³Ã¼¼ö, 2018³â¿¡¼­ 2022³â
    • COVID-19 °¨¿°ÁõÀÇ ¿µÇ⠺м®

Á¦4Àå µ¿¹°¿ë Á¤¸ÆÁÖ»ç¾× ½ÃÀå : Á¦Ç° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • µ¿¹°¿ë Á¤¸ÆÁÖ»ç¾× ½ÃÀå : Á¦Ç° º¯µ¿ ºÐ¼®°ú ½ÃÀå Á¡À¯À², 2022³â ¹× 2030³â
  • µî ÀåÁ¤Áú¾×
  • ÇÕ¼º ÄÝ·ÎÀ̵å
  • Ç÷¾×Á¦Àç
  • Æ÷µµ´ç¾×
  • ºñ°æ±¸ ¿µ¾ç

Á¦5Àå µ¿¹°¿ë Á¤¸ÆÁÖ»ç¾× ½ÃÀå : ÀûÀÀÁõ ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • µ¿¹°¿ë Á¤¸ÆÁÖ»ç¾× ½ÃÀå : ÀûÀÀÁõ º¯µ¿ ºÐ¼®°ú ½ÃÀå Á¡À¯À², 2022³â ¹× 2030³â
  • ´ç´¢º´¼º ÄÉÅæ»êÁõ
  • ÃéÀå¿°
  • źÀú±Õ
  • ¸¸¼º ½ÅÀ庴
  • ±âŸ

Á¦6Àå µ¿¹°¿ë Á¤¸ÆÁÖ»ç¾× ½ÃÀå : µ¿¹° À¯Çü ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • µ¿¹°¿ë Á¤¸ÆÁÖ»ç¾× ½ÃÀå : µ¿¹° À¯Çü º¯µ¿ ºÐ¼®°ú ½ÃÀå Á¡À¯À², 2022³â ¹× 2030³â
  • ¹Ý·Áµ¿¹°
  • »ý»ê µ¿¹°

Á¦7Àå µ¿¹°¿ë Á¤¸ÆÁÖ»ç¾× ½ÃÀå : ÃÖÁ¾ ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • µ¿¹°¿ë Á¤¸ÆÁÖ»ç¾× ½ÃÀå : ÃÖÁ¾ ¿ëµµ º¯µ¿ ºÐ¼®°ú ½ÃÀå Á¡À¯À², 2022³â ¹× 2030³â
  • µ¿¹° º´¿ø
  • ¿¬±¸±â°ü
  • ±âŸ

Á¦8Àå µ¿¹°¿ë Á¤¸ÆÁÖ»ç¾× ½ÃÀå : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®

  • Áö¿ª Àü¸Á
  • µ¿¹°¿ë Á¤¸ÆÁÖ»ç¾× ½ÃÀå : Áö¿ª º¯µ¿ ºÐ¼®°ú ½ÃÀå Á¡À¯À², 2022³â ¹× 2030³â
  • ºÏ¹Ì
    • SWOT ºÐ¼®
    • ºÏ¹ÌÀÇ µ¿¹°¿ë Á¤¸ÆÁÖ»ç¾× ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018³â¿¡¼­ 2030³â
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • SWOT ºÐ¼®
    • À¯·´ÀÇ µ¿¹°¿ë Á¤¸ÆÁÖ»ç¾× ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018³â¿¡¼­ 2030³â
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • µ§¸¶Å©
    • ½º¿þµ§
    • ³ë¸£¿þÀÌ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • SWOT ºÐ¼®
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ µ¿¹°¿ë Á¤¸ÆÁÖ»ç¾× ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018³â¿¡¼­ 2030³â
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • ű¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • SWOT ºÐ¼®
    • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ µ¿¹°¿ë Á¤¸ÆÁÖ»ç¾× ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018³â¿¡¼­ 2030³â
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • SWOT ºÐ¼®
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ µ¿¹°¿ë Á¤¸ÆÁÖ»ç¾× ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018³â¿¡¼­ 2030³â
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • Äí¿þÀÌÆ®

Á¦9Àå °æÀï »óȲ

  • ÁÖ¿ä ±â¾÷ °³¿ä
    • Participant's Overview
    • Product Benchmarking
    • Financial Performance
    • Strategic Initiatives
  • ÁøÃâ ±â¾÷
  • È÷Æ®¸Ê ºÐ¼®/±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Ç ºÐ¼®
  • Àü·« ¸ÅÇÎ
  • ±âŸ ÁÖ¿ä ½ÃÀå ±â¾÷ ¸®½ºÆ®
ksm 23.09.06

Veterinary Intravenous Solutions Market Growth & Trends

The global veterinary intravenous solutions market size is expected to reach USD 2.67 billion by 2030, expanding at a CAGR of 8.37% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth is driven by increasing awareness of animal welfare, advancements in veterinary healthcare, increasing pet ownership, and the increasing prevalence of illnesses such as anthrax, pancreatitis, and mouth disease. The advancements in veterinary medicine have expanded the range of treatment options available for animals. Veterinary clinics and hospitals are equipped with advanced diagnostic and treatment facilities, including intravenous fluid administration systems, which contribute to the growth of the market.

The development of advanced IV fluid delivery systems designed specifically for veterinary use has made the administration process more efficient, accurate, and safe. These technological advancements, such as specialized infusion pumps and fluid monitoring systems, have positively impacted the veterinary intravenous solutions industry by enhancing patient care and reducing the risk of complications. Rising disposable income levels in many regions have led to increased spending on pet healthcare. Pet owners are more willing to invest in high-quality veterinary care, including intravenous fluid therapy, which contributes to the growth of the market.

The post-COVID-19 impact on the veterinary intravenous solutions industry is still unfolding as the global situation continues to evolve. The COVID-19 pandemic recovery has led to an increased demand for veterinary intravenous solutions as part of the standard care provided to animals during surgeries, treatments, and critical care situations. The economic impact of the pandemic affected many individuals and businesses, including pet owners and veterinary clinics. Financial constraints may have influenced the decision-making process for pet owners, potentially leading to a decrease in non-essential veterinary procedures and treatments, including the use of IV fluids.

Moreover, the adoption of veterinary intravenous (IV) fluid solutions in North America is relatively high due to various factors such as veterinary education programs in North America emphasizing the importance of IV fluid therapy and its appropriate use in different clinical situations. Veterinarians and veterinary technicians receive extensive training in the administration, monitoring, and management of IV fluids, ensuring their competent use in practice. Furthermore, veterinary professionals in North America strive to provide high-quality care for animals. IV fluid therapy is a crucial component of comprehensive veterinary treatment, and its adoption is driven by the commitment to optimize patient care and support the recovery and well-being of animals.

Veterinary Intravenous Solutions Market Report Highlights

  • Based on product, the isotonic crystalloids segment dominated the market with a share of over 42% in 2022. To restore and maintain hydration and electrolyte balance in animals, fluid therapy in veterinary medicine frequently uses isotonic crystalloid solutions
  • Based on animal type, the companion animals segment dominated the market in 2022. Many homes regularly keep companion animals as pets, especially dogs and cats. Pet ownership leads to a large demand for veterinary intravenous solutions, as these animals frequently require intravenous therapy for a variety of health issues, surgeries, or critical care situations
  • Based on indication, the Diabetic Ketoacidosis (DKA) segment dominated the market in 2022
  • Based on end-use, the veterinary hospital segment dominated the market with a revenue share of over 55% in 2022, as more people are taking their pets to veterinarian facilities for care. IV hydration therapy is frequently used in veterinary hospitals as a crucial part of patient care
  • North America held the highest revenue share of over 38.0% of the market in 2022. In North America, there is a high rate of pet ownership, with many homes keeping companion animals like dogs, cats, and small mammals

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Research Methodology
  • 1.3. Information Procurement
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Veterinary Intravenous Solutions Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing demand for companion animals and pets
      • 3.2.1.2. Increasing prevalence of illnesses such as anthrax, pancreatitis, mouth disease
      • 3.2.1.3. Increase in the need for nutrition-rich food, focus on food safety, and increasing care for animals
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Lack of awareness regarding the use of veterinary intravenous solutions
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
  • 3.3. Veterinary Intravenous Solutions Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political & Legal Landscape
      • 3.3.2.2. Economic and Social Landscape
      • 3.3.2.3. Technological landscape
    • 3.3.3. Pricing Analysis
    • 3.3.4. Estimated Animal Population, by key countries, 2018 to 2022
    • 3.3.5. COVID-19 Impact Analysis

Chapter 4. Veterinary Intravenous Solutions Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Veterinary Intravenous Solutions Market: Product Movement Analysis & Market Share, 2022 & 2030
  • 4.3. Isotonic crystalloids
    • 4.3.1. Isotonic Crystalloids Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Synthetic colloids
    • 4.4.1. Synthetic Colloids Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Blood products
    • 4.5.1. Blood Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Dextrose solutions
    • 4.6.1. Dextrose Solutions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Parenteral nutrition
    • 4.7.1. Parenteral Nutrition Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Veterinary Intravenous Solutions Market: Indication Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Veterinary Intravenous Solutions Market: Indication Movement Analysis & Market Share, 2022 & 2030
  • 5.3. Diabetic Ketoacidosis
    • 5.3.1. Diabetic Ketoacidosis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Pancreatitis
    • 5.4.1. Pancreatitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Anthrax
    • 5.5.1. Anthrax Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Chronic Kidney Disease
    • 5.6.1. Chronic Kidney Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Veterinary Intravenous Solutions Market: Animal Type Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Veterinary Intravenous Solutions Market: Animal Type Movement Analysis & Market Share, 2022 & 2030
  • 6.3. Companion Animals
    • 6.3.1. Companion Animals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Production Animals
    • 6.4.1. Production Animals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Veterinary Intravenous Solutions Market: End-use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Veterinary Intravenous Solutions Market: End-Use Movement Analysis & Market Share, 2022 & 2030
  • 7.3. Veterinary Hospitals
    • 7.3.1. Veterinary Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Research Institutes
    • 7.4.1. Research Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Others
    • 7.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Veterinary Intravenous Solutions Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Outlook
  • 8.2. Veterinary Intravenous Solutions Market: Regional Movement Analysis & Market Share, 2022 & 2030
  • 8.3. North America
    • 8.3.1. SWOT Analysis
    • 8.3.2. North America Veterinary Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.3.3. The U.S.
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Regulatory Framework
      • 8.3.3.3. U.S. Veterinary Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.3.4. Canada
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Regulatory Framework
      • 8.3.4.3. Canada Veterinary Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Europe
    • 8.4.1. SWOT Analysis
    • 8.4.2. Europe Veterinary Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. UK
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Regulatory Framework
      • 8.4.3.3. UK Veterinary Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. Germany
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Regulatory Framework
      • 8.4.4.3. Germany Veterinary Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.5. France
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Regulatory Framework
      • 8.4.5.3. France Veterinary Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.6. Italy
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Regulatory Framework
      • 8.4.6.3. Italy Veterinary Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.7. Spain
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Regulatory Framework
      • 8.4.7.3. Spain Veterinary Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.8. Denmark
      • 8.4.8.1. Key Country Dynamics
      • 8.4.8.2. Regulatory Framework
      • 8.4.8.3. Denmark Veterinary Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.9. Sweden
      • 8.4.9.1. Key Country Dynamics
      • 8.4.9.2. Regulatory Framework
      • 8.4.9.3. Sweden Veterinary Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.10. Norway
      • 8.4.10.1. Key Country Dynamics
      • 8.4.10.2. Regulatory Framework
      • 8.4.10.3. Norway Veterinary Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. SWOT Analysis
    • 8.5.2. Asia Pacific Veterinary Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Japan
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Regulatory Framework
      • 8.5.3.3. Japan Veterinary Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.4. China
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Regulatory Framework
      • 8.5.4.3. China Veterinary Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.5. India
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Regulatory Framework
      • 8.5.5.3. India Veterinary Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.6. South Korea
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Regulatory Framework
      • 8.5.6.3. South Korea Veterinary Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.7. Australia
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Regulatory Framework
      • 8.5.7.3. Australia Veterinary Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.8. Thailand
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Regulatory Framework
      • 8.5.8.3. Thailand Veterinary Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Latin America
    • 8.6.1. SWOT Analysis
    • 8.6.2. Latin America Veterinary Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. Brazil
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Regulatory Framework
      • 8.6.3.3. Brazil Veterinary Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. Mexico
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Regulatory Framework
      • 8.6.4.3. Mexico Veterinary Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Argentina
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Regulatory Framework
      • 8.6.5.3. Argentina Veterinary Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Middle East & Africa
    • 8.7.1. SWOT Analysis
    • 8.7.2. Middle East & Africa Veterinary Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.7.3. South Africa
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Regulatory Framework
      • 8.7.3.3. South Africa Veterinary Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.7.4. Saudi Arabia
      • 8.7.4.1. Key Country Dynamics
      • 8.7.4.2. Regulatory Framework
      • 8.7.4.3. Saudi Arabia Veterinary Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.7.5. UAE
      • 8.7.5.1. Key Country Dynamics
      • 8.7.5.2. Regulatory Framework
      • 8.7.5.3. UAE Veterinary Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.7.6. Kuwait
      • 8.7.6.1. Key Country Dynamics
      • 8.7.6.2. Regulatory Framework
      • 8.7.6.3. Kuwait Veterinary Intravenous Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Key Company Profiles
    • 9.1.1. Participant's Overview
    • 9.1.2. Product Benchmarking
    • 9.1.3. Financial Performance
    • 9.1.4. Strategic Initiatives
      • 9.1.4.1. Merck & Co., Inc.
      • 9.1.4.2. Dechra Veterinary Products
      • 9.1.4.3. Sypharma
      • 9.1.4.4. Animalcare
      • 9.1.4.5. B. Braun SE
      • 9.1.4.6. Woods Consulting, LLC
      • 9.1.4.7. Baxter
      • 9.1.4.8. Fresenius Kabi
  • 9.2. Participant Categorization
  • 9.3. Heat Map Analysis/ Company Market Position Analysis
  • 9.4. Strategy Mapping
  • 9.5. List of Other Key Market Players
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦